Payment overview · 2025
General Payments
$777.67
39 reported records · 18 companies
Healthcare provider profile · identity verified
Erin Dulaney Britt, DO
Allopathic & Osteopathic Physicians|Internal Medicine · CULLMAN, AL · NPI 1790282655
Verified facts
What the public records show
CMS Open Payments records show Erin Dulaney Britt, DO received $777.67 in general payments during 2025 across 39 reported records.
ABBVIE INC. accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nexletol, Ozempic, Rybelsus, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexletol by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Soliqua 100-33 by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $183.97 | 23.7% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.23 | 12.4% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$58.97 | 7.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.11 | 6.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.16 | 6.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.30 | 6.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $45.64 | 5.9% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $44.36 | 5.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.43 | 3.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.96 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.47 | 3.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.30 | 2.6% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.42 | 2.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.97 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.35 | 2.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.84 | 2.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.50 | 2.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.69 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $777.67 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $112.95 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.02 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.02 | 5 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $63.33 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $58.97 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $53.11 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $46.30 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $45.64 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.01 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.01 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.67 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.67 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $27.43 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 272 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
272 | 46 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 600 | 138 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 500 | 158 |
| Atorvastatin Calcium | Atorvastatin Calcium | 439 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 435 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 425 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 419 | 131 |
| Omeprazole | Omeprazole | 398 | 117 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 396 | 67 |
| Losartan Potassium | Losartan Potassium | 386 | 133 |
| Lisinopril | Lisinopril | 317 | 98 |
| Clonazepam | Clonazepam | 299 | 45 |
| Montelukast Sodium | Montelukast Sodium | 293 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 76 |
| Eliquis | Apixaban | 272 | 46 |
| Tramadol Hcl | Tramadol Hcl | 260 | 51 |
| Trazodone Hcl | Trazodone Hcl | 254 | 88 |
| Alprazolam | Alprazolam | 234 | 41 |
| Metformin Hcl | Metformin Hcl | 233 | 81 |
| Furosemide | Furosemide | 216 | 83 |
| Meloxicam | Meloxicam | 208 | 60 |
| Famotidine | Famotidine | 196 | 73 |
| Zolpidem Tartrate | Zolpidem Tartrate | 196 | 30 |
| Pregabalin | Pregabalin | 180 | 40 |
| Sertraline Hcl | Sertraline Hcl | 180 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 165 | 56 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 163 | 43 |
| Metformin Hcl Er | Metformin Hcl | 157 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 52 |
| Potassium Chloride | Potassium Chloride | 156 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 51 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 140 | 75 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 136 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 135 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 132 | 33 |
| Celecoxib | Celecoxib | 131 | 44 |
| Atenolol | Atenolol | 129 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 36 |
| Prednisone | Prednisone | 125 | 85 |
| Quetiapine Fumarate | Quetiapine Fumarate | 125 | 29 |
| Lorazepam | Lorazepam | 123 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 53 |
| Farxiga | Dapagliflozin Propanediol | 120 | 23 |
| Ozempic | Semaglutide | 120 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 37 |
| Carvedilol | Carvedilol | 114 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 39 |
| Buspirone Hcl | Buspirone Hcl | 105 | 33 |
| Jardiance | Empagliflozin | 105 | 18 |
| Bupropion Xl | Bupropion Hcl | 100 | 39 |
| Donepezil Hcl | Donepezil Hcl | 100 | 22 |
| Januvia | Sitagliptin Phosphate | 91 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 12 |
| Ezetimibe | Ezetimibe | 85 | 29 |
| Mounjaro | Tirzepatide | 79 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 75 | suppressed |
| Temazepam | Temazepam | 71 | suppressed |
| Allopurinol | Allopurinol | 69 | 23 |
| Glimepiride | Glimepiride | 67 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 20 |
| Simvastatin | Simvastatin | 66 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 20 |
| Mirtazapine | Mirtazapine | 60 | 21 |
| Primidone | Primidone | 59 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 17 |
| Spironolactone | Spironolactone | 56 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 48 |
| Estradiol | Estradiol | 55 | 24 |
| Fluconazole | Fluconazole | 53 | 37 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Eszopiclone | Eszopiclone | 52 | 13 |
| Synthroid | Levothyroxine Sodium | 52 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 17 |
| Ondansetron Odt | Ondansetron | 44 | 23 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Cefdinir | Cefdinir | 43 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | 16 |
| Topiramate | Topiramate | 42 | suppressed |
| Valsartan | Valsartan | 42 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 12 |
| Memantine Hcl | Memantine Hcl | 40 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | 11 |
| Gemtesa | Vibegron | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 37 | 17 |
| Meclizine Hcl | Meclizine Hcl | 37 | 19 |
| Nystatin | Nystatin | 37 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | 12 |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | 15 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Finasteride | Finasteride | 34 | 12 |
| Ramipril | Ramipril | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 11 |
| Promethazine Hcl | Promethazine Hcl | 32 | 12 |
| Baclofen | Baclofen | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 15 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | 13 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 25 |
| Linzess | Linaclotide | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 22 |
| Diazepam | Diazepam | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 13 |
| Rybelsus | Semaglutide | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Xtampza Er | Oxycodone Myristate | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Nexletol | Bempedoic Acid | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | 11 |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $777.67 · 39 records | ABBVIE INC. | ABRYSVO, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, INSPIRE, Kerendia, Korlym, LEQEMBI, MINIMED 780G, NEXLETOL, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, RECORLEV, REXULTI, Rybelsus, Symbravo, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error